GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (XTAE:BWAY) » Definitions » Gross Profit

BrainsWay (XTAE:BWAY) Gross Profit : ₪103.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is BrainsWay Gross Profit?

BrainsWay's gross profit for the three months ended in Sep. 2024 was ₪27.6 Mil. BrainsWay's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was ₪103.0 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BrainsWay's gross profit for the three months ended in Sep. 2024 was ₪27.6 Mil. BrainsWay's Revenue for the three months ended in Sep. 2024 was ₪37.5 Mil. Therefore, BrainsWay's Gross Margin % for the quarter that ended in Sep. 2024 was 73.52%.

BrainsWay had a gross margin of 73.52% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 11 years, the highest Gross Margin % of BrainsWay was 80.59%. The lowest was 73.77%. And the median was 77.78%.

Warning Sign:

BrainsWay Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.2%.


BrainsWay Gross Profit Historical Data

The historical data trend for BrainsWay's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Gross Profit Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.24 60.76 82.42 71.66 83.91

BrainsWay Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.06 24.09 24.35 26.94 27.60

Competitive Comparison of BrainsWay's Gross Profit

For the Medical Devices subindustry, BrainsWay's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Gross Profit distribution charts can be found below:

* The bar in red indicates where BrainsWay's Gross Profit falls into.



BrainsWay Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BrainsWay's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=113.609 - 29.696
=83.9

BrainsWay's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=37.537 - 9.94
=27.6

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪103.0 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BrainsWay's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=27.6 / 37.537
=73.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BrainsWay  (XTAE:BWAY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BrainsWay had a gross margin of 73.52% for the quarter that ended in Sep. 2024 => Durable competitive advantage


BrainsWay Gross Profit Related Terms

Thank you for viewing the detailed overview of BrainsWay's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.